First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Global phase 2 data in TNBC look similar to earlier results in China.
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Studies presented at ASH show this to be true only up to a point.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.